Posts by: Alice Melão

News

The U.S. Food and Drug Administration has granted Investigational New Drug status to Unum Therapeutics’ ACTR707, in combination with Genentech’s Rituxan (rituximab), for treating non-Hodgkin lymphoma. Regulators’ approval applies to relapsed or refractory ... Read more

July 13, 2017

FDA Committee Recommends Approval of Mylotarg to Treat Newly Diagnosed AML

News

The Oncologic Drug Advisory Committee (ODAC) of the U.S. Food and Drug Administration (FDA) supports the approval of Pfizer’s Mylotarg (gemtuzumab ozogamicin), in combination with standard chemotherapy, for the treatment ... Read more

July 6, 2017

EU Approves Besponsa for Adults with B-Cell Acute Lymphoblastic Leukemia

ALL, News

The European Union has approved Pfizer‘s Besponsa as a treatment for adults with a type of B-cell leukemia. The authorization applies to patients with relapsed or refractory CD22-positive B-cell acute lymphoblastic ... Read more

July 5, 2017

FDA Approves New Diagnostic Tool for Leukemias and Lymphomas

News

The U.S. Food and Drug Administration (FDA) has approved a new laboratory test to help clinicians detect leukemia and lymphoma cells using a technique called flow cytometry. The ClearLLab Reagents, ... Read more

June 29, 2017June 29, 2017

Adcetris-Chemotherapy Combo Lengthens the Time for Hodgkin’s Lymphoma to Progress, Trial Shows

News

Adding Adcetris (brentuximab vedotin) to standard chemotherapy significantly lengthens the time it takes for Hodgkin’s lymphoma to progress, or for a patient to die, according to an updated of Phase 3 clinical ... Read more

June 28, 2017June 28, 2017

Tazemetostat Benefits Follicular and B-cell Lymphoma Patients with EZH2 Mutations, Phase 2 Trial Shows

News

Twelve of 13 patients with relapsed or refractory follicular lymphoma (FL) and mutations of the EZH2 enzyme responded either fully or partially to treatment with tazemetostat, according to a Phase 2 clinical trial. Tazemetostat, ... Read more

June 26, 2017June 26, 2017

ADC Reports Positive Phase 1 Results on Antibody-drug Conjugate ADCT-301 for Hodgkin’s, NHL

News

Preliminary results from a Phase 1 trial testing ADC Therapeutics’ ADCT-301 to treat relapsed or refractory Hodgkin’s and non-Hodgkin’s lymphoma (NHL) demonstrated the medication’s therapeutic potential with good overall response rates and low ... Read more

June 23, 2017June 23, 2017

Truxima Shows Similar Safety and Efficacy Results to Rituxan in Phase 3 Trial

News

Results from a Phase 3 trial have shown that Truxima (CT-P10), developed by Celltrion Healthcare, has a similar efficacy and safety profile as Genetech’s Rituxan (rituximab) for the treatment of advanced-stage follicular lymphoma. ... Read more

June 21, 2017

Seattle Genetics Asks FDA to Approve Adcetris for Expanded Set of Lymphoma Patients

News

Seattle Genetics is asking the U.S. Food and Drug Administration to approve Adcetris (brentuximab vedotin) for an expanded set of cutaneous T-cell lymphoma patients. The agency has yet to authorize Adcetris for CTCL. A supplemental Biologics ... Read more

June 2, 2017June 2, 2017

Potential Treatment for a Number of Blood Cancers, ASN002, Enters Phase 2 Trial

News

Following positive results in a dose–escalation trial with non-Hodgkin’s lymphoma (NHL) patients, a Phase 2 trial will now evaluate a new kinase inhibitor, ASN002, in the treatment of several hematological ... Read more